A
Adele Morganti
Researcher at Actelion
Publications - 20
Citations - 1906
Adele Morganti is an academic researcher from Actelion. The author has contributed to research in topics: Bosentan & Macitentan. The author has an hindex of 11, co-authored 20 publications receiving 1738 citations.
Papers
More filters
Journal ArticleDOI
Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
Xavier Jaïs,Andrea Maria D'Armini,Pavel Jansa,Adam Torbicki,Marion Delcroix,Hossein Ardeschir Ghofrani,Marius M. Hoeper,Irene M. Lang,Eckhard Mayer,Joanna Pepke-Zaba,Loïc Perchenet,Adele Morganti,Gérald Simonneau,Lewis J. Rubin +13 more
TL;DR: A positive treatment effect (TE) of bosentan over placebo on PVR was demonstrated and no improvement was observed in exercise capacity, and the role of medical therapy in patients with CTEPH was defined.
Journal ArticleDOI
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial
Marco Matucci-Cerinic,Christopher P. Denton,Daniel E. Furst,Maureen D. Mayes,Vivien Hsu,Patrick H. Carpentier,Fredrick M. Wigley,Carol M. Black,Barri J. Fessler,Peter A. Merkel,Janet E. Pope,Nadera J. Sweiss,Mittie K. Doyle,Mittie K. Doyle,Bernhard Hellmich,Thomas A. Medsger,Adele Morganti,Fabrice Kramer,Joseph H. Korn,James R. Seibold +19 more
TL;DR: Bosentan treatment reduced the occurrence of new DUs in patients with SSc but had no effect on DU healing and may be a useful adjunct in the management of patients withSSc with recurrent DUs.
Journal ArticleDOI
Effects of long-term bosentan in children with pulmonary arterial hypertension.
Erika B. Rosenzweig,D. Dunbar Ivy,Allison C. Widlitz,Aimee Doran,Lori Claussen,Delphine Yung,Steven H. Abman,Adele Morganti,Ngoc Nguyen,Robyn J. Barst +9 more
TL;DR: Data suggest that bosentan, an oral endothelin ET(A)/ET(B) receptor antagonist, with or without concomitant prostanoid therapy, is safe and efficacious for the treatment of PAH in children.
Journal ArticleDOI
Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial
Ganesh Raghu,Rachel Million-Rousseau,Adele Morganti,Loïc Perchenet,Juergen Behr,Nicole S L Goh,Allan R. Glanville,Michael Musk,Peter Hopkins,Dale Lien,Christopher T. Chan,J. D. Rolf,Pearce G. Wilcox,P. G. Cox,Hélène Manganas,Vincent Cottin,Dominique Valeyre,B. Walleart,S. Andreas,Claus Neurohr,Andreas Guenther,N. Schönfeld,Andrea Koch,Mordechai R. Kramer,R. Breuer,I. Ben-Dov,G. Fink,Yehuda Schwarz,Carlo Albera,Marco Confalonieri,Cesare Saltini,Sergio Harari,M. Flezar,M. Greenblatt,G. J. Ras,Ferran Morell,José Luis Álvarez-Sala,Antonio Xaubet,A. Sueiro,M. J. Linares,Magnus Sköld,Oya Kayacan,Nesrin Mogulkoc,Andrew L. Chan,Jeffrey T. Chapman,Joseph Parambil,N. Ettinger,Jeffrey A. Golden,Keith C. Meyer,Jeffrey J. Swigris,Gordon L. Yung,Danielle Antin-Ozerkis,P. K. Mohabir,Lewis J. Wesselius,J.A. De Andrade,Francis Cordova,Zeenat Safdar,M. Wencel +57 more
TL;DR: Long-term exposure to macitentan was well tolerated with a similar, low incidence of elevated hepatic aminotransferases in each treatment group, and the primary objective was not met.
Journal ArticleDOI
Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases
Christopher P. Denton,Janet E. Pope,Hans-Hartmut Peter,Armando Gabrielli,A. Boonstra,F.H.J. van den Hoogen,G. Riemekasten,S. De Vita,Adele Morganti,M. Dolberg,O. Berkani,Loïc Guillevin +11 more
TL;DR: In most patients, bosentan was associated with improvement or stability of clinical status, and the 92% estimate for survival at 48 weeks is a significant achievement in this patient population.